A detailed history of Jane Street Group, LLC transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 91,084 shares of MIRM stock, worth $3.86 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
91,084
Previous 122,664 25.75%
Holding current value
$3.86 Million
Previous $4.19 Million 15.29%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$33.68 - $44.74 $1.06 Million - $1.41 Million
-31,580 Reduced 25.75%
91,084 $3.55 Million
Q2 2024

Aug 14, 2024

BUY
$23.57 - $34.85 $189,950 - $280,856
8,059 Added 7.03%
122,664 $4.19 Million
Q1 2024

May 15, 2024

BUY
$24.92 - $30.02 $2.07 Million - $2.49 Million
82,896 Added 261.43%
114,605 $2.88 Million
Q4 2023

Feb 14, 2024

SELL
$27.14 - $34.93 $920,941 - $1.19 Million
-33,933 Reduced 51.69%
31,709 $936,000
Q3 2023

Nov 14, 2023

SELL
$24.63 - $32.85 $4.48 Million - $5.98 Million
-182,032 Reduced 73.5%
65,642 $2.07 Million
Q2 2023

Aug 14, 2023

BUY
$23.51 - $30.09 $4.76 Million - $6.09 Million
202,379 Added 446.8%
247,674 $6.41 Million
Q1 2023

May 15, 2023

BUY
$19.19 - $24.1 $869,211 - $1.09 Million
45,295 New
45,295 $1.09 Million
Q2 2022

Aug 16, 2022

SELL
$18.42 - $27.5 $167,548 - $250,140
-9,096 Reduced 46.47%
10,476 $204,000
Q1 2022

May 17, 2022

BUY
$15.5 - $23.93 $303,366 - $468,357
19,572 New
19,572 $431,000
Q4 2021

Feb 15, 2022

SELL
$13.05 - $19.35 $204,571 - $303,330
-15,676 Closed
0 $0
Q3 2021

Nov 16, 2021

BUY
$13.95 - $20.18 $218,680 - $316,341
15,676 New
15,676 $312,000

Others Institutions Holding MIRM

About Mirum Pharmaceuticals, Inc.


  • Ticker MIRM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,751,700
  • Market Cap $1.56B
  • Description
  • Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...
More about MIRM
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.